Menu Search
Equities

Genoway SA

ALGEN:PAR

Genoway SA

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (EUR)3.46
  • Today's Change0.09 / 2.67%
  • Shares traded35.34k
  • 1 Year change-15.61%
  • Beta0.4649
Data delayed at least 15 minutes, as of Nov 08 2024 16:35 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in EURIncome statement in EURView more

Year on year Genoway SA grew revenues 17.55% from 17.05m to 20.05m while net income improved 101.55% from 777.75k to 1.57m.
Gross margin92.34%
Net profit margin5.86%
Operating margin7.64%
Return on assets3.90%
Return on equity7.20%
Return on investment5.40%
More ▼

Cash flow in EURView more

In 2023, cash reserves at Genoway SA fell by 621.78k. However, the company earned 3.06m from its operations for a Cash Flow Margin of 15.28%. In addition the company used 2.00m on investing activities and also paid 1.69m in financing cash flows.
Cash flow per share0.4277
Price/Cash flow per share8.57
Book value per share2.04
Tangible book value per share1.40
More ▼

Balance sheet in EURView more

Genoway SA has a Debt to Total Capital ratio of 26.39%, a lower figure than the previous year's 35.32%.
Current ratio1.92
Quick ratio1.81
Total debt/total equity0.3585
Total debt/total capital0.2639
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.